脱フコシル化モノクローナル抗体 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "脱フコシル化モノクローナル抗体" in Japanese language version.

refsWebsite
Global rank Japanese rank
2nd place
6th place
4th place
24th place
1st place
1st place
low place
low place
6,219th place
low place

doi.org

  • “Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies”. Expert Opin Biol Ther 6 (11): 1161–73. (2006). doi:10.1517/14712598.6.11.1161. PMID 17049014. 
  • “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity”. Nat. Biotechnol. 17 (2): 176–80. (February 17, 1999). doi:10.1038/6179. PMID 10052355. 
  • “Obinutuzumab: first global approval”. Drugs 74 (1): 147–54. (2014). doi:10.1007/s40265-013-0167-3. PMID 24338113. 
  • Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). “Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.”. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. https://eprints.soton.ac.uk/410615/1/Resubmission_Yu_Manuscript_and_table.pdf. 
  • “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity”. Biotechnol. Bioeng. 87 (5): 614–22. (September 5, 2004). doi:10.1002/bit.20151. PMID 15352059. 

nih.gov

pubmed.ncbi.nlm.nih.gov

  • “Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies”. Expert Opin Biol Ther 6 (11): 1161–73. (2006). doi:10.1517/14712598.6.11.1161. PMID 17049014. 
  • “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity”. Nat. Biotechnol. 17 (2): 176–80. (February 17, 1999). doi:10.1038/6179. PMID 10052355. 
  • “Obinutuzumab: first global approval”. Drugs 74 (1): 147–54. (2014). doi:10.1007/s40265-013-0167-3. PMID 24338113. 
  • Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). “Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.”. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. https://eprints.soton.ac.uk/410615/1/Resubmission_Yu_Manuscript_and_table.pdf. 
  • “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity”. Biotechnol. Bioeng. 87 (5): 614–22. (September 5, 2004). doi:10.1002/bit.20151. PMID 15352059. 

roche.com

soton.ac.uk

eprints.soton.ac.uk

web.archive.org